Why the study?
Does irbesartan 150 mg once daily improve biochemical parameters in overweight hypertensive patients?
Does irbesartan 150 mg once daily improve biochemical parameters in overweight hypertensive patients?
Irbesartan 150 mg daily for six months significantly improved fasting plasma glucose, HOMA-IR, and lipid profiles in overweight hypertensive patients.
Irbesartan was associated with metabolic improvements in overweight hypertensives; hypothesis-generating and should not yet change practice.
Irbesartan is an angiotensin receptor type 1 blocker which is used for treatment of hypertension. It has been found in various that some angiotensin receptor type 1 blockers induce peroxisome proliferator-activated receptor gamma. Present is designed to study the effect of irbesartan on various biochemical parameters in overweight hypertensive patients. AND METHODS overweight hypertensive patients were selected for study and they were given 150 mg irbesartan once daily and their parameters like lipid profile, insulin concentration, FPG and HOMA-IR was measured basal and at the end of study is six months. plasma glucose decreased from 93.8 mg/dL to 85.5 with ‘p’- value <0.00001. HOMA-IR score decreased from 2.702 to 1.99. We have observed that all the biochemical parameters like body weight, BMI, fasting plasma glucose, insulin, total , LDL–cholesterol, triglyceride, HOMA-IR and blood pressure under study decreased. administration of irbesartan improved blood pressure, insulin, HOMA-IR and lipid profile in hypertensive overweight .
No takes yet. Share an insight, caveat, or question.
M et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: